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Abstract 
 
Patients with Parkinson disease are prescribed dopamine agonists such as pramipexole to 
improve motor symptoms. Several studies have found that patients taking dopaminergic 
medication develop impulse control disorders. In contrast, other studies suggest that some 
behaviors become less impulsive with pramipexole. We evaluated the performance of 20 young, 
healthy participants who received pramipexole (0.5 mg) and 20 participants who received 
placebo, on the Go/No-Go, the Stop Signal Task, and the Balloon Analogue Risk Task. We 
found that the pramipexole group had more timed out Go trials on the Go/No-Go task than the 
placebo group, suggesting reduced motor impulsivity. There were no differences between the 
two groups’ performance on the other impulsivity tasks. This pattern of results is in line with the 
theory that impulsivity consists of a motor and a cognitive aspect, and that pramipexole might 
decrease motor, but not cognitive impulsivity. 
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Chapter 1: Introduction 
 
1.0 Literature review 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder in which dopamine- 
producing neurons degenerate in the substantia nigra pars compacta (SNpc), and to a much lesser 
extent in the neighbouring ventral tegmental area (VTA), leading to motor and cognitive 
impairments. The hallmark motor symptoms of PD include tremor at rest, rigidity (of limbs and 
the trunk), and bradykinesia (slowness of movement; Dauer & Przedborski, 2003; Jankovic, 
2008). Impairments in cognition, specifically in frontostriatal functions (such as learning, 
memory, and executive functions) are also recognized as an indisputable feature of PD (Aarsland 
& Kurz, 2010; Barone et al., 2011). PD is predominantly an age-associated disorder with a sharp 
increase in prevalence after the age of 60, although there are cases of PD with onset before 50 
(de Lau & Breteler, 2006). The estimated prevalence of PD in adults older than 60 is around 1%, 
with some studies finding rates closer to 2– 3%, making it the second most common age-
associated disorder (de Lau & Breteler, 2006). The etiology of PD is not fully understood and 
there is no cure for the disease. Motor symptoms are well mitigated by medication, whereas non-
motor symptoms, which present more varied deficits and do not respond as well to medication, 
tend to be the major cause of impairments and institutionalization (Aarsland, Larsen, Tandberg, 
& Laake, 2000; Aarsland, Zaccai, & Brayne, 2005; Dauer & Przedborski, 2003; Halliday, 
Leverenz, Schneider, & Adler, 2014; Seppi et al., 2011). Non-motor deficits in PD are complex 
and likely have several causes, including PD pathology, side effects of dopaminergic medication, 
and adverse interactions between PD pathology and medication effects (Aarsland, Brønnick, 
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Larsen, Tysnes, & Alves, 2009; Bosboom, Stoffers, & Wolters, 2004; Caballol, Martí, & Tolosa, 
2007; Rowe et al., 2008; Seppi et al., 2011). 
1.1 Pathophysiology of PD 
Physiologically, PD is marked by a selective and rapid degeneration of dopaminergic cells 
projecting to the striatum from the SNpc. The striatum comprises the caudate nucleus, the 
putamen, and the nucleus accumbens (Obeso et al., 2008; Voorn, Vanderschuren, Groenewegen, 
Robbins, & Pennartz, 2004). The striatum is often described in terms of a ventral and a dorsal 
portion – the dorsal striatum (DS), and the ventral striatum (VS). Although no clear boundaries 
exist separating the DS and the VS, the areas tend to be subdivided along relatively consistent 
demarcations (see Figure 1), usually setting the boundary between the dorsal parts of the caudate 
and putamen (collectively called the DS), and the ventral portion of the putamen as well as the 
nucleus accumbens (collectively called the VS; Voorn et al., 2004). The division is in large part 
supported by behavioral and cognitive differences in the functioning of these different areas 
(Obeso et al., 2008; Voorn et al., 2004). Neuroanatomically, there are also subtle 
cytoarchitectural changes along different points of the striatum, although there is no clear 
anatomical difference marking a boundary between the DS and VS (Voorn et al., 2004). 
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Figure 1: Commonly accepted subdivision of the striatum into the DS and the VS. Adapted 
from Telzer, 2016. 
 
Cells in the SNpc, which project to the DS, deteriorate much more rapidly than cells in the VTA, 
which project to the VS (Kish, Shannak, & Hornykiewicz, 1988). This results in a greater overall 
loss of dopamine in the SNpc and the DS and their afferents, compared to the VTA and the VS. 
This dopaminergic deficiency in the SNpc-DS pathway produces the cardinal motor symptoms 
of PD including tremor, rigidity, and bradykinesia (Dauer & Przedborski, 2003; Jankovic, 2008).  
Rather than being responsible for the execution of motor commands per se, the SNpc-DS system 
is involved in the selection of actions (Balleine, Delgado, & Hikosaka, 2007). Additionally, the 
SNpc-DS system is involved in procedural learning and stimulus-response learning, for example, 
when learning a new motor sequence or a response to a new stimulus (Packard & Knowlton, 
4 
 
2002; White & McDonald, 2002). The DS is also involved in the performance of less habitual 
and more considered actions (Ali, Green, Kherif, Devlin, & Price, 2009; Benke, Delazer, Bartha, 
& Auer, 2003; Cameron, Watanabe, Pari, & Munoz, 2010; MacDonald, Seergobin, Tamjeedi, & 
Owen, 2014; Macdonald & Monchi, 2011; Mestres-Missé, Turner, & Friederici, 2012; 
Robertson, Hiebert, Seergobin, Owen, & MacDonald, 2015). The medial part of the DS has also 
been shown to affect inhibitory control of motor actions (Eagle & Robbins, 2003), which is 
required to stop or prevent an action from being executed.  
 
Similarly, the VTA-VS system can be thought of as a mediator of motor behaviors, but more 
specifically in the context of reward and reinforcement-based behaviors (Cardinal, Parkinson, 
Hall, & Everitt, 2002; McBride, Murphy, & Ikemoto, 1999). Reversal learning is mediated by 
the VTA-VS system, which involves the extinction of previously reinforced behaviors (Cools, 
Clark, Owen, & Robbins, 2002). Evidence also suggests its involvement in spatial learning 
(Setlow, 1997). In summary, both the DS and the VS are involved in a range of cognitive 
functions, thus their dysfunction can contribute to non-motor impairments in PD (Atallah, 
Lopez-Paniagua, Rudy, & O’Reilly, 2007; Dirnberger & Jahanshahi, 2013; Grahn, Parkinson, & 
Owen, 2009; Nagano-Saito, Martinu, & Monchi, 2014). 
 
Ultimately, the striatum, which receives inputs from nearly all areas of the cortex, influences 
actions through its inhibition or disinhibition of the thalamus, which then feeds back into the 
initial region of the cortex where the signal originated (Obeso et al., 2008). The striatum is 
predominantly populated by medium spiny neurons, which send inhibitory GABAergic signals 
along two main pathways known as the direct pathway and the indirect pathway. The direct 
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pathway functions through the activation of D1 dopaminergic receptors, and begins at the 
striatum, making inhibitory connections with the globus pallidus pars interna (GPi). The GPi 
forms inhibitory connections with the thalamus, so inhibition of the GPi actually disinhibits the 
thalamus. As a result, stimulation of the direct pathway via D1 receptors leads to a disinhibition 
of the thalamus, which then sends excitatory feedback amplifying the original signal. The 
indirect pathway contains cells with D2 receptors. The striatum projects inhibitory connections 
to the globus pallidus pars externa (GPe), which projects inhibitory connections to the 
subthalamic nucleus. The subthalamic nucleus forms excitatory connections with the GPi, which, 
as previously discussed, inhibits the thalamus. Thus, stimulation of the indirect pathway inhibits 
the GPe, which disinhibits the subthalamic nucleus. The subthalamic nucleus then excites the 
GPi, and the GPi inhibits the thalamus. The net result of stimulation of the indirect pathway is 
the inhibition of the thalamus, and a dampening of the original signal (Obeso et al., 2008). 
1.2 Medication to treat motor symptoms 
Although there is no cure for PD, medication sufficiently alleviates the motor symptoms caused 
by dopamine deficiency in the SNpc, especially in the earlier stages of disease. Medication to treat 
PD, which primarily acts on dopaminergic cells and receptors, is titrated with the aim of restoring 
dopamine to the deficient SNpc-DS system. The two most effective drug types used to treat PD 
are the dopamine precursor L-3,4-dihydroxyphenylalanine (levodopa), and dopamine agonists 
(such as pramipexole, ropinirole, rotigotine, and apomorphine; Connolly & Lang, 2014). 
Levodopa is a dopamine precursor that leads to the production of dopamine. In the striatum, it acts 
presynaptically on dopaminergic cells and is converted to dopamine, making up for the decreased 
dopamine from the SNpc (Lang & Lees, 2002). In contrast, dopamine agonists act post-
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synaptically, by attaching to, and activating dopamine receptors directly (Brooks, 2000; Quinn, 
1995). The actions of both types of drugs cause a net increase of  activated dopaminergic receptors 
in the striatum However, the acute dopamine activity caused by the drugs is markedly different 
from the consistent release of low doses of dopamine that occurs in an unimpaired dopaminergic 
system (Lang & Lees, 2002). These drugs are currently titrated to treat the motor symptoms of PD 
resulting from the deficiency in the SNpc-DS system (Connolly & Lang, 2014), with little regard 
for the effects on more complex behaviors and cognition that are also mediated by the striatum.   
 
Both drug types are associated with the development of behavioral and cognitive complications. 
Research shows that whereas some functions improve when patients are on medication, others 
become worse (Cools, Barker, Sahakian, & Robbins, 2001; MacDonald et al., 2011; Macdonald 
& Monchi, 2011). Continued use of levodopa leads to levodopa-induced dyskinesia (LID), a 
condition marked by jerky, involuntary and purposeless movements that usually appear at the 
time levodopa effects are at their peak (Ahlskog & Muenter, 2001; Carta, Carlsson, Kirik, & 
Bjorklund, 2007). Review studies estimate that over the course of 4-6 years of treatment, around 
40% of patients develop LID, and the prevalence increases to between 60-89% by 10 years of 
treatment (Ahlskog & Muenter, 2001; Fabbrini, Brotchie, Grandas, Nomoto, & Goetz, 2007; 
Zesiewicz, Sullivan, & Hauser, 2007). To treat LID, patients are commonly given lower doses of 
levodopa, but this increases the duration of the OFF period (i.e. when the anti-parkinsonian 
effects of levodopa wear off and motor symptoms worsen) and makes the disease more difficult 
to manage. Treatment with dopamine agonists leads to fewer instances of dyskinesia than 
treatment with levodopa (Parkinson Study Group, 2000), so early treatment with dopamine 
agonists is preferable.  
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However, the prolonged use of dopamine agonists, such as pramipexole, has been associated with 
the development of impulse control disorders (ICDs) in patients with PD (Aarsland & Kurz, 2010; 
Burdick et al., 2014; Pontone, Williams, Bassett, & Marsh, 2006). ICDs are characterized by the 
occurrence of impulsive actions and behaviors such as gambling, binge eating, hyper-sexuality, 
and uncontrollable spending. Weintraub and colleagues, (2010) found that patients taking 
dopamine agonists are at a 2 – 3.5 times greater risk of developing an ICD, but suggested that 
additional demographic and clinical factors may influence the development of ICDs.  
 
Most studies investigating the effects of dopaminergic medication on cognition and impulsivity 
have been conducted on PD patients (Macdonald & Monchi, 2011; Poletti & Bonuccelli, 2013), 
which presents difficulty in interpreting the effects of dopaminergic medication. Typical PD 
samples vary widely in terms of age, disease duration and time of onset, as well as overall disease 
severity. To better understand whether the association between dopamine agonists and the 
development of ICDs is due to the medication, due to an interaction between medication and PD 
pathology, or due to an interaction with other demographic factors associated with PD, it is 
necessary to investigate the effects of the medication in isolation from these other confounding 
variables.  
 
Additionally, the cognitive pathology of PD patients is complex. First, there is strong evidence 
that some cognitive deficits result from striatal dopamine deficiency (Barone et al., 2011; 
Bosboom et al., 2004; Caballol et al., 2007). Second, in addition to dopaminergic pathways, 
dysregulation in cholinergic (Bohnen et al., 2006; Gilman, 2010), serotonergic (Huot, Fox, & 
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Brotchie, 2011; Ye et al., 2014)  and noradrenergic (Del Tredici & Braak, 2013; Vazey & Aston-
Jones, 2012; Weintraub, 2010) pathways appears to also contribute to cognitive deficits in PD. 
Dopamine sensitization following prolonged use of dopaminergic medication (Fenu, Wardas, & 
Morelli, 2009) could further complicate the relationship between dopamine agonists in PD and 
the appearance of ICDs. There is also evidence showing that patients with PD have reduced 
levels of the dopamine transporter DAT, which regulates synaptic dopamine levels, and this 
decrease could exacerbate the effects of dopamine to pathological levels (Harrington, Augood, 
Kingsbury, Foster, & Emson, 1996; Kalia & Lang, 2015; Kordower et al., 2013; Voon, 2009). 
Thus, with many variables potentially affecting cognition in PD, any effects of medication are 
difficult to interpret.  
 
Dopamine agonists are also increasingly prescribed outside the context of PD, so it is important 
to understand the effects of this medication in isolation from PD. Individuals with restless leg 
syndrome (RLS; Comella, 2002; Högl, Paulus, Clarenbach, & Trenkwalder, 2006; Hornyak, 
Scholz, Kohnen, & Bengel, 2014; Trenkwalder, Hening, Montagna, & Oertel, 2008; Zintzaras, 
Kitsios, Papathanasiou, & Konitsiotis, 2010)  and in some cases dystonia (Cloud & Jinnah, 2010; 
Jankovic, 2013) are treated with dopamine agonists. Additionally, the use of dopamine agonists 
is being investigated in the treatment of depression (Goto, Yoshimura, Kakihara, & Shinkai, 
2006; Hori & Kunugi, 2012, 2013; Howland, 2012; Papakostas, 2006) , drug addiction (Carroll, 
Howell, & Kuhar, 1999; Streeter, Hennen, Ke, & Jensen, 2005) and to address withdrawal 
symptoms (Makhinson & Gomez-Makhinson, 2014; Ohmura, Jutkiewicz, Zhang, & Domino, 
2011). Therefore, investigating the effects of dopamine agonists on impulsivity in healthy 
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controls is necessary to avoid the many factors that might interact with the medication when 
studied in clinical populations. 
1.3 Pramipexole effects on impulsivity  
Pramipexole is a nonergot dopamine agonist, which unlike levodopa does not promote the 
production of dopamine, but directly stimulates dopaminergic receptors. Research in rats 
(Piercey, Walker, Feldpausch, & Camacho-Ochoa, 1996) and humans (Gerlach et al., 2003) has 
shown that pramipexole has a high binding affinity to dopaminergic receptors in the striatum. 
Pramipexole is an agonist on the D2 subfamily of receptors. This includes the D2, D3, and D4 
subtypes (Missale, Nash, Robinson, Jaber, & Caron, 1998). It binds primarily to the D2/D3 
dopamine receptors and is used to treat PD as well as restless-leg-syndrome (Ferini-Strambi et 
al., 2008; Montplaisir, Nicolas, Denesle, & Gomez-Mancilla, 1999; Reichmann, Brecht, Koster, 
Kraus, & Lemke, 2003). Pramipexole’s binding of the D2 receptors has been considered 
responsible for the improvement in motor symptoms in PD, whereas its binding to D3 receptors 
might be responsible for some improvement in depressive symptoms (Guttman & Jaskolka, 
2001). 
 
Studies investigating the effects of pramipexole on impulsivity have yielded results suggesting it 
increases some aspects of impulsivity and decreases others. Experiments with rats have 
repeatedly demonstrated that single doses of pramipexole increase impulsive, gambling-like 
behavior in reward related tasks (Holtz, Tedford, Persons, Grasso, & Napier, 2016; Johnson, 
Madden, Brewer, Pinkston, & Fowler, 2011; Madden, Johnson, Brewer, Pinkston, & Fowler, 
2010). In human studies, experiments have demonstrated that a single dose of pramipexole 
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affects the reward network. Participants show a preference for riskier rewards and a decrease in 
brain activity associated with the attainment of a reward (Riba, Krämer, Heldmann, Richter, & 
Münte, 2008). Another neuroimaging experiment showed that pramipexole increased the 
connectivity between the nucleus accumbens and the anterior insula, but decreased the 
connectivity between the nucleus accumbens and the prefrontal cortex (Ye, Hammer, Camara, & 
Münte, 2011). In addition to the studies finding an association between pramipexole and ICDs 
and impulsivity, these results suggest that pramipexole disrupts reward-related neural pathways, 
leading to impulsive behavior.  
 
In contrast, Fera  and colleagues (2007) found that PD patients were more accurate on the 
incongruent condition of a Stroop task when they were on dopaminergic medication than when 
they were off medication, suggesting better cognitive control in the face of ambiguity. 
Specifically, in the modified Stroop task, patients had to select (via button press) one of four 
color words (green, blue, red, yellow) describing either the color of a square presented in the 
centre (Congruent condition) or the color of a color word printed in different ink in the centre of 
the screen (e.g. the word ‘Blue’ printed in red ink). In another study, Caillava-Santos and 
colleagues (2015) found that patients with PD were more quick to respond to incongruent trials 
of a Stroop task on medication compared to when they were off medication. In an experiment by 
Hiebert and colleagues (2014) PD patients had to learn stimulus-response associations that were 
either congruent or incongruent spatially. Patients responded faster to congruent and incongruent 
trials when they were off medication compared to when they were on medication, which is 
evidence of attenuated impulsivity by dopaminergic medication. An experiment by van Wouwe 
and colleagues (2016) elegantly dissociated impulse capture from impulse control in PD patients 
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on and off medication by employing the Dual Process Activation Suppression framework to 
examine performance on a Simon task. In the context of the framework, inhibiting an impulse 
consists of two processes: 1) impulse capture, which is the initial activation and initiation of a 
response to a stimulus and 2) reactive impulse control, which acts to prevent and inhibit an 
activated impulsive response. The theory states that in conflicting situations an incorrect 
impulsive response is initiated through a direct processing route, and that inhibition of this 
impulse is carried out through a deliberate, goal-oriented processing route (Ridderinkhof, 2002). 
The framework also provides analytical tools that allow to examine the distribution of responses 
and separately quantify the strength of impulse capture and of reactive impulse control. In the 
experiment, which employed the Simon task, participants had to press a button with their right or 
left hand in response to a colored circle appearing on the left or right side of a screen. A blue 
circle required a response with the left hand, and a green circle, with the right hand. The task 
consisted of Congruent trials (e.g. a blue circle, requiring a left-hand response, appearing on the 
left side) and Noncongruent trials (a blue circle appearing on the right side). The distribution of 
responses to the Simon task ranges from quick impulsive and incorrect responses (a measure of 
impulse capture) to slow, deliberate responses (when impulse control processes have built up). 
The results indicated that PD patients had better impulse control on medication than off, and that 
impulse capture was not affected by medication. Thus, only the ability to control the execution of 
an impulsive response was affected by the dopaminergic medication. In summary, it appears that 
dopaminergic medication slows down or attenuates some impulsive processes in patients with 
PD, while also exacerbating impulsivity in other, more complex behaviors that are reward-
dependent.   
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An explanation of the seemingly contradictory effects of pramipexole on impulsivity can be 
offered by looking at impulsivity as a multifaceted phenomenon. Impulsivity is a complex 
construct entailing many different aspects of thought and behavior. Broadly, impulsivity can be 
defined as the inability to inhibit premature or pre-potent actions (i.e. actions that have 
previously been reinforced and become primed), along with a tendency towards risky or less 
calculated choices (Dalley, Everitt, & Robbins, 2011). Thus, it is clear that impulsivity involves 
multiple, possibly distinct behaviors.  
 
Impulsivity can be divided into two domains: motor impulsivity and cognitive impulsivity 
(Antonelli, Ray, & Strafella, 2011). A principal component analysis (PCA) on 11 of the most 
common questionnaires and tasks used to measure impulsivity, including the Go/No-Go task 
(GNG), the Stop Signal Task (SST), and the Kirby Temporal Discounting task, supports a 
division of impulsivity into multiple aspects (Nombela, Rittman, Robbins, & Rowe, 2014). The 
analysis revealed 4 components, which were classified by the authors as follows: 1) Interference 
and response conflict in decision making, 2) Motor response inhibition, 3) Delay aversion and 
time estimation, 4) Temporal discounting. The components were dissociable and correlated with 
distinct demographic measures.  
 
A larger PCA by Caswell and colleagues (2015) using a sample of healthy young adults further 
demonstrated that impulsivity is a heterogeneous construct. Specifically, their aim was to test 
whether impulsivity was composed of different subtypes, including motor-impulsivity, temporal-
impulsivity, and reflective-impulsivity. They also aimed to test whether tasks that are used 
interchangeably to assess subtypes of impulsivity have shared factor loadings and correlations. 
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The authors tested 160 participants on 10 behavioral and one self-report measure of impulsivity. 
A PCA revealed four components as well, though the authors did not explicitly classify each 
component. However, component 1 had a high loading of the SST, which is likely to be the 
motor-impulsivity component. Curiously, the GNG task, another classic impulsivity measure, did 
not load on the same component. Component 2 had a high loading of the Information Sampling 
Task and the Matching Familiar Figures Task, leading the authors to classify it as a reflective-
impulsivity component. Component 3 had a high loading of the Immediate Memory Task. 
Component 4 had a high loading of the Delay Discounting Task and the Monetary Choice 
Questionnaire, which was classified as the temporal-impulsivity component. The effects of 
pramipexole on impulsivity therefore are likely a combination of its influence on multiple 
aspects, cognitive and motor. It appears that pramipexole might increase some aspects of 
cognitive impulsivity (i.e. risk taking) but decrease other aspects, such as motor impulsivity. 
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1.4 Measures of impulsivity 
Over the years, the complex and multi-faceted construct of impulsivity has been measured by a 
variety of behavioral tasks (See Figure 2). 
 
Figure 2: Multiple aspects of impulsivity and commonly used impulsivity tasks. Adapted from 
Winstanley, Olausson, Taylor, & Jentsch, (2010). 
 
The GNG task is a common measure of impulsivity and motor control, because it requires the 
inhibition of a highly primed action. In the basic version of a GNG task, participants are told to 
press a button as quickly as possible when they see a stimulus appear in the centre of the screen. 
Trials proceed in quick succession such that participants are primed to make a quick button-
press. In this way, the action becomes highly primed and pre-potent. On some trials, a different 
stimulus appears, and participants are told that on these trials no action needs to be taken, that is, 
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they must withhold the pre-potent impulse to press the button. Behavioral outcome measures on 
the GNG can be reaction time (RT) and accuracy (omission errors, commission errors, overall 
accuracy, or a ratio of these measures). The GNG task has been used with healthy participants as 
well as clinical populations to study impulsivity and differences in cognitive control (Antonelli et 
al., 2014; Georgiev, Dirnberger, Wilkinson, Limousin, & Jahanshahi, 2016; Hamidovic, Kang, & 
de Wit, 2008; Reynolds, Ortengren, Richards, & de Wit, 2006; Verbruggen & Logan, 2008; 
Woltering, Liu, Rokeach, & Tannock, 2013).  
 
We are aware of only one experiment that employed the GNG task in a group of healthy 
participants to study the effects of pramipexole on impulsivity. Hamidovic and colleagues (2008) 
administered pramipexole or placebo to healthy participants who then performed a GNG task. 
They found no effects of pramipexole on any measures of the GNG. However, they employed a 
GNG task with a 50:50 Go:NoGo ratio, whereas most GNG experiments use higher Go:NoGo 
ratios to ensure the development of a pre-potent response. Thus, it is unlikely that their GNG task 
established a pre-potent, impulse-like response in participants.    
 
The SST is a task that also measures impulsivity and the ability to stop a pre-potent action. In the 
task, participants choose an appropriate response when presented with a stimulus. Participants 
must respond as soon as the stimulus is presented; these are called Go trials. On Stop trials, the 
stimulus is followed by a Stop signal. When presented the Stop signal, participants must try to 
stop their response on that trial. Difficulty is adjusted by changing the delay between the Go 
stimulus and the Stop signal, known as the Stop Signal Delay (SSD). When the SSD is short 
(meaning the Stop signal occurs almost simultaneously with the Go stimulus) stopping a 
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response is easier than when the SSD is longer. The accepted theory behind the SST is that of the 
‘race model’ (Logan, 1994; Logan, Cowan, & Davis, 1984). The model posits that performance 
on the SST reflects a race between a Go process and a Stop process, and that the two are 
independent of each other. The two processes compete simultaneously, with each having its own 
threshold for completion, and the one that reaches its threshold earlier results in a response (or 
lack thereof). The Go process has its own RT distribution, which is easily observed by presenting 
participants with stimuli in the absence of Stop-signals. The Stop process is not observable 
directly, because its successful execution results in no overt response and is, in fact, indicated by 
the absence of a response or action. Thus, the Stop process must be calculated using the RT 
distribution of the Go process and the proportion of successfully inhibited Stop trials fitted to 
that distribution (Logan et al., 1984). We are not aware of any studies in healthy participants that 
investigated the effects of pramipexole on performance of the SST.  
 
The Balloon Analogue Risk Task (BART; Lejuez et al., 2002) is a task that simulates a risk-
taking situation in the form of a game. In the BART, participants inflate a virtual balloon; the 
more pumps they make to inflate the balloon, the more virtual money they earn. They are 
presented several balloons, and on each trial they can cash out at any point, or continue inflating 
the balloon, until at some predetermined, but unknown and varying pump number, the balloon 
explodes and they lose all potential earnings for that balloon. The task has been used to study 
impulsivity and risk taking in healthy participants (Chiu et al., 2012; Fukunaga, Brown, & Bogg, 
2012; Hamidovic et al., 2008; Rao, Korczykowski, Pluta, Hoang, & Detre, 2008; Reynolds et al., 
2006).  
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Impulsivity can also be measured using questionnaires and self report measures. These measures 
do not always correlate with results from behavioral tasks, thus it is possible that they capture 
different aspects of impulsivity, or that self reported impulsivity and behavioral impulsivity are 
dependent on different processes. Among these, the Barratt Impulsiveness Scale (BIS), and the 
Sensation Seeking Scale have commonly been used.  
 
Though reports of pramipexole use and the development of impulsivity and ICDs are common in 
PD, and there is a clear need to study the effects of the drug in healthy controls to disentangle PD 
pathology from medication effects, we are aware of only one other study that investigated 
pramipexole’s effects on impulsivity tasks in healthy controls. Hamidovic and colleagues (2008) 
conducted a within-subjects study in young, healthy participants who over three sessions 
received placebo, 0.25 mg, and 0.5 mg of pramipexole. The participants completed several 
questionnaires assessing impulsivity, a simple RT and a two-choice RT task, as well as the GNG, 
the BART, a delayed discounting task, and a card perseveration task. The authors found no 
effects of pramipexole on any of the impulsivity tasks. 
1.5 Aims of the study 
In this study, we aimed to explore the effects of a single dose of pramipexole on different aspects 
of impulsivity in a sample of young healthy controls. We used a between-subjects, double-
blinded, placebo-controlled design. Both groups completed the three impulsivity tasks (the GNG, 
SST, and BART), and measures of impulsivity and impulsivity-related traits using questionnaires 
(The BIS and the Sensation Seeking Scale), as well as other questionnaires to assess general 
cognition.  
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We hypothesized, based on the results appearing in the literature on impulsivity and 
dopaminergic medication, that pramipexole will decrease motor impulsivity, measured through 
the GNG and SST tasks. On the GNG, this will be evidenced by slower responding, which might 
also lead to fewer errors. On the SST, decreased impulsivity might result in a longer SSRT. The 
effects of dopamine agonists on reward-dependent impulsivity seem to be opposite, in that 
pramipexole should increase risk-taking on the BART, which is a measure of risk-reward and 
gambling. This pattern of results would be in line with the theory that pramipexole and dopamine 
agonists have opposing effects on different aspects of impulsivity.  
Chapter 2: Methods 
2.0 Participants 
This study was approved by the Health Sciences Research Ethics Board (REB #102018) of the 
University of Western Ontario (See  
). Participants were recruited from the University of Western Ontario through word of mouth and 
advertisements posted around campus. Forty-five young healthy adults were enrolled in the study 
(28 females, 17 males). Exclusion criteria were: a history of neurological (e.g., stroke, seizures) 
or psychiatric conditions (including clinical depression, hallucinations), family history of more 
than one first-degree relative with PD, history of alcohol or drug abuse, any risk factors 
associated with taking pramipexole (including taking monoamine oxidase inhibitors, history of 
cardiovascular disease, peptic ulcers). All potential participants were pre-screened during a brief 
phone interview, and completed an in-person screening form. All participants provided informed 
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consent before beginning the experiment in accordance with the Declaration of Helsinki (1991). 
All participants were provided with monetary compensation for their time. 
2.1 Materials 
 
2.1.1 Health and Demographics and Safety Screening questionnaires 
Copies of the ‘Health and Demographics’ and the ‘Safety Screening’ questionnaires are found in 
Error! Reference source not found. and Error! Reference source not found.. These questionnaires we
re administered to collect demographic data and ensure that in addition to the safety screening 
completed over the phone, there were no contraindications to receiving pramipexole, and that 
participants did not meet any exclusion criteria.  
2.1.2 Pramipexole and placebo capsules 
Participants orally ingested an opaque yellow capsule containing either 0.5 mg of pramipexole 
(tablet form, fitted into the capsule) or cornstarch. Capsules were prepared by the investigator and 
each capsule was kept inside an individual envelope with a unique code generated by an 
independent lab associate, ensuring that the investigator remained blind when giving participants 
the capsule. The chosen dose of pramipexole (0.5 mg) is based on dosages used in other studies in 
healthy participants (Hamidovic et al., 2008; Pizzagalli et al., 2008; Riba et al., 2008), as this was 
the dose shown to produce observable behavioral effects with minimal adverse events. This dose 
is commonly prescribed and falls within the therapeutic range. Pramipexole acts primarily on the 
D2 family of dopamine receptors, and reaches maximum plasma concentration after approximately 
two hours, which is when participants completed the impulsivity tasks. It has a terminal half-life 
of eight hours in young adults and about 12 hours in older adults (Putri et al., 2016; Wright, Sisson, 
Ichhpurani, & Peters, 1997). 
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2.1.3 Questionnaires 
The Bond-Lader Visual Analogue Scale (BL-VAS; Bond & Lader, 1974) is a 16-item 
questionnaire assessing subjective feelings associated with alertness (alert—drowsy), calmness 
(tense—relaxed), and general mood (antagonistic—friendly). We presented participants with 
combinations of such opposing adjectives and asked them to place a mark with a pencil on a line 
stretching between the two adjectives corresponding to their current feeling. The distance from 
each adjective is measured in millimeters and used to calculate a total score for each cluster. See 
Error! Reference source not found.. 
 
The American National Adult Reading Test (ANART; Nelson, 1982) is a quick, commonly used 
measure of verbal intelligence employed in research in multiple populations. Due to its ease of 
administration and good overall validity (Bright, Jaldow, & Kopelman, 2002), the ANART was 
chosen as a measure of verbal intelligence in this experiment. Participants were instructed to read 
out loud a list of 50 words ranging in difficulty in their irregularity of grapheme-phoneme 
correspondence (e.g. aisle, hyperbole). They were told to pronounce them correctly, and to make 
an attempt even if they are not sure. Total number of correctly pronounced words was used as the 
final score. See Error! Reference source not found.. 
 
The Montreal Cognitive Assessment (MOCA; Nasreddine et al., 2005) is a measure used to screen 
for dementia and mild cognitive impairment. It evaluates basic visuospatial abilities, immediate 
and delayed recall as well as working memory, executive functioning and attention, language 
abilities, and time and place orientation. It is scored out of 30 points, with scores 26 and greater 
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indicating normal cognition. The test is commonly used with older adults. However, it was used 
in this experiment with young adults to ensure that groups were well-matched in terms of their 
cognitive functions as well as to parallel the procedures employed with older adults to allow for 
future between-subject comparisons. See Error! Reference source not found.. 
 
The Controlled Oral-Word Association Test (using letters ‘F’, ‘A’, ‘S’; COWAT FAS; Benton, 
Hamsher & Silvan, 1994) is a measure of verbal fluency. Participants were asked to generate words 
out loud that begin with a given letter of the alphabet. They were allowed 60 seconds to do so, 
with the instructions stating that they should avoid proper nouns (e.g., Bob, Boston) and repetitions 
of the same word (i.e. perseveration errors) or same word-root with a different ending (e.g., Run, 
Running, Runners). The COWAT was administered as a control measure for verbal fluency and 
intelligence. See Error! Reference source not found.. 
 
The Barratt Impulsiveness Scale- version 11 (BIS; Patton, Stanford, & Barratt, 1995) is a 30-item 
questionnaire assessing different aspects of impulsivity. It has been extensively used to study 
impulsivity in research and clinical settings (Stanford et al., 2009) and consists of measures of 
attentional, motor, and non-planning impulsivity. It is rated on a Likert scale ranging from 1 = 
Rarely/Never to 4 = Almost always/Always. The BIS was chosen in this experiment to control for 
trait impulsivity that might account for differences between participants’ impulsivity scores on the 
behavioral tasks. See Error! Reference source not found.. 
 
The Sensation Seeking Scale (Zuckerman, Eysenck, & Eysenck, 1978) consists of 40 pairs of 
statements in which the participant must select the statement that most applies to them and their 
22 
 
beliefs. It is a measure of sensation seeking, composed of scores for Boredom Susceptibility, 
Disinhibition, Experience Seeking, and Thrill/Adventure Seeking. See Error! Reference source not f
ound.. 
 
The Epworth Sleepiness Scale (Johns, 1991) is a measure of fatigue. Participants were asked to 
rate how likely they are to fall asleep/ doze off (0 = “Would never doze” to 3 = ”High chance of 
dozing”) in eight different scenarios (e.g. “Sitting and reading” and “Sitting quietly after a lunch 
without alcohol”). Total score was used as a final measure of fatigue. We included this measure to 
be able to control for trait fatigue. See Error! Reference source not found.. 
 
The Oxford Happiness questionnaire (Hills & Argyle, 2002) consists of 29 statements which 
participants rate on a 6-point Likert scale from 1 = strongly disagree, to 6 = strongly agree. The 
statements assess general well-being (e.g. “I am well satisfied about everything in my life” and “I 
am not particularly optimistic about the future). The questionnaire was administered to assess 
participants’ trait happiness and well-being to parallel with other experiments and allow for 
between-subjects comparisons.  See Error! Reference source not found. 
 
The Beck Depression Inventory (BDI; Beck, Steer, & Brown, 1996) was administered as an 
additional screening measure for depression. The BDI consists of 21 group of statements about 
thoughts and feelings experienced in the past two weeks including the day of testing. Participants 
circled the statement that is closest to their feelings/thoughts and the corresponding number. The 
total was used as an index of depressive symptoms, with scores of 21 or higher meeting depression 
criteria. See Error! Reference source not found.. 
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The Beck Anxiety Inventory (BAI; Beck & Steer, 1990) measures general anxiety. It asks 
participants to rate how much they have been bothered by various common symptoms of anxiety 
(e.g. “Wobbliness in legs”, “Face flushed”) during the past week, including the day of the testing. 
Participants put a checkmark under options ranging from “Not at all” to “Severely- it bothered me 
a lot”, which were then converted to numerical scores and summed. See Error! Reference source n
ot found..  
 
The Starkstein Apathy Scale (SAS; Starkstein et al., 1992) presents participants with 16 statements 
assessing apathy. Participants put a check mark under options ranging from “Not at all” to “A lot” 
for different statements related to apathy (e.g. “Does anything interest you?” and “Do you need a 
push to get started on things?”). The answers were then converted to numerical values and used to 
calculate a total apathy score. See Error! Reference source not found..  
 
2.2 Equipment 
The computer tasks were performed on a 22.0” monitor (LG Flatron W2242TQ) with a resolution 
of 1600 x 900 pixels and a desktop (LG model 73821B-10) using the Windows 7 Professional 
operating system. The screen was placed approximately 50 cm away from the participant. A 
keyboard (Logitech K120) was used to record participant responses. 
 
2.3 Primary impulsivity measures 
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2.3.1 Go/No-Go Task 
The GNG is a widely-used task measuring motor impulsivity and the ability to inhibit motor 
responses (Antonelli et al., 2014; Ballanger et al., 2009; Kiehl, Liddle, & Hopfinger, 2000; Petit, 
Kornreich, Noël, Verbanck, & Campanella, 2012; Rubia et al., 2001; Woltering et al., 2013). The 
version we used in the current study, the simple two-stimuli GNG, was chosen due to its ability to 
establish a highly pre-potent response in participants, which must be inhibited on certain trials. 
During a trial, participants would either see an X, which was the ‘Go’ stimulus, and then press the 
spacebar as quickly as possible, or see a K, which was the ‘NoGo’ stimulus to which any response 
must be inhibited (i.e. must not press any key). The task consisted of four blocks, each containing 
64 trials. Of these trials, 48 were ‘Go’ trials, and 16 were ‘NoGo’ trials, constituting a distribution 
of 75% ‘Go’ trials to 25% ‘NoGo’ trials. This distribution was chosen to maximize ‘Go’ response 
prepotency, and is consistent with the parameters used in other studies (Boucher et al., 2012; Kiehl 
et al., 2000; Liddle, Kiehl, & Smith, 2001; Nieuwenhuis, Yeung, Wildenberg, & Ridderinkhof, 
2003).  
 
Trials started with a small grey fixation cross presented in the center of a dark background for 500 
milliseconds (ms), followed by a stimulus presented in white, either an X or a K for up to 500 ms. 
If participants made a response before the timeout period, an inter-trial interval of 2000 ms 
(including the response time) followed, after which the fixation cross for the next trial appeared. 
These parameters ensured the development of a quick, pre-potent motor response that would 
require inhibitory control to suppress. 
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2.3.2 Stop Signal Task 
The SST is used to measure control over motor impulsivity, that is, the ability to stop an ongoing 
action. The task has been widely used to study impulsivity in various populations (Bedard et al., 
2002; Eagle, Baunez, et al., 2008; Williams, Ponesse, Schachar, Logan, & Tannock, 1999). In the 
two-choice version of the task, used in the current experiment, participants were presented one of 
two stimuli and needed to press one of two corresponding keys as quickly as possible. In our 
experiment, participants were asked to press the ‘Z’ key when they saw the letter ‘X’, and the ‘/’ 
key when they saw the letter ‘O’. Participants were instructed to press these keys as quickly as 
possible after seeing the stimuli – these were the Go trials. On some trials, referred to as Stop-
signal trials, an auditory signal would sound after the presentation of the stimulus, which indicated 
that participants needed to stop their keypress. The task consisted of 128 trials broken into two 
blocks of 64 trials. In each block, 25% of the trials were Stop-signal (16 trials) and the remaining 
48 trials were Go trials. Inter-trial interval was set at 2000 ms (including response time). Each trial 
started with the presentation of a grey fixation cross in the centre of the screen for 500 ms, followed 
by the stimulus which appeared on the screen until a response was recorded or 1250 ms elapsed. 
The initial SSD was set at 250 ms, with a staircase adjustment method increasing the SSD by 50 
ms after successfully inhibited Stop-signal trials, and decreasing SSD by 50 ms after failed Stop-
signal trials. This adjustment was used so that that participants successfully inhibited 
approximately 50% of the Stop-signal trials, which is necessary for analysis of the SST.   
 
Participants were told that on some trials the signal would appear shortly after presentation of the 
stimulus, which would make stopping their keypress easy, whereas on other trials the signal would 
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appear after a slight delay, making stopping more difficult. Participants were encouraged to press 
the associated keys as quickly as they could, and were told that when they hear the signal they 
should do their best to stop, although on some trials stopping would nearly impossible. That is, 
they were told that appropriate performance of the task entails being unable to stop on some trials. 
They were explicitly informed that they should not slow their responding on Go trials to reduce 
the number of failed stops. This was done in accordance with instructions established previously 
(e.g. Logan et al., 1984) meant to encourage participants to provide an accurate and proportional 
number of successful and unsuccessful Stop-signal trials.  
 
2.3.3 Balloon Analogue Risk Task 
The BART has been previously used in healthy populations to study risk taking. Developed by 
Lejuez and colleagues (2002), the BART correlates with multiple established measures of 
impulsivity (Lejuez et al., 2002), including self-reports of different dimensions of impulsivity (i.e. 
venturesomeness, risk taking, reward seeking) and self-reports of impulsive behavior (i.e. drug 
use, alcohol consumption, risky sexual behavior, gambling). Further, the BART accounts for 
variance in impulsivity that is not captured by any of the above measures, suggesting it taps into 
an understudied or undetected aspect of impulsivity. This makes the BART a suitable task to 
capture what is likely a cognitive, reward seeking and risk discounting aspect of impulsivity.  
 
We used a modified version of the original BART task (Lejuez et al., 2002). The version used for 
this experiment was modified to be shorter due to pilot data indicating that longer sessions were 
less likely to lead to measurable differences. The balloons were presented one at a time in the 
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center of the screen, surrounded by a display of the total earned amount, and the current reward in 
the temporary bank. Each pump increased the reward in the temporary bank by 5 cents. Participants 
could pump the balloon until they decided to collect their reward from that balloon, or until the 
balloon exploded. To collect their earnings participants pressed the ‘Z’ key and saw a smiley face 
accompanied by sound, indicating a win. Alternatively, if they reached a predetermined point at 
which the balloon exploded, known as the breakpoint, they saw a sad face and heard a popping 
sound, indicating they lost their current reward in the temporary bank. Participants were not aware 
of each balloon’s breakpoint. Across all 30 balloons, and across each block of 10 balloons, the 
average breakpoint was 32 pumps. The range of the number of allowed pumps was between 1 and 
64 pumps. For the task in the current study, a single randomly generated list of trial breakpoints, 
with the constraints noted above, was used for each participant to minimize interactions between 
different lists and individual differences of participants.  
2.4 Physiological measures 
Heart rate (HR) and blood pressure readings (i.e. diastolic and systolic) were taken using an 
automated blood pressure cuff (Omron model BP785N). These readings were taken to monitor 
participants’ well-being and ensure that they did not experience significant physiological side 
effects from pramipexole, and to account for physiological changes across group or related to 
medication condition when analyzing behavioral data.  
2.5 Procedure 
All potential participants were pre-screened during a phone interview before being scheduled for 
the experiment. During the phone interview, they were provided information about pramipexole 
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and the testing session. The interviewer also went over a safety screening questionnaire to ensure 
that potential participants met none of the exclusion criteria for receiving pramipexole.  
 
Upon arrival at the lab, potential participants completed another safety screening questionnaire. 
They signed the consent form and completed a health and demographics questionnaire. Following 
this, they completed the BL-VAS and their HR and blood pressure were measured, before they 
received the capsule. This is referred to as Time 1 (T1). They were provided information about the 
double blinding process and were reminded that in the less likely event that they should feel any 
side effects during the session, they should inform the experimenter. A timer set to two hours was 
started as soon as the participants ingested the capsule. The participants then completed the 
ANART, the MOCA, the COWAT FAS, the BIS, the Sensation Seeking Scale, the Epworth 
Sleepiness Scale, and the Oxford Happiness Questionnaire. This was followed by practice trials 
for each of the computer tasks. 
 
Participants were then given a break with the duration dependent on how much time was left on 
the timer until the two hours since capsule ingestion elapsed. During the break, participants could 
do anything as long as they remained in the testing room. The investigator came back every 15 
minutes to check on the participants and make sure they were feeling fine and were not 
experiencing side effects.  
 
After two hours passed since capsule ingestion, when drug concentration was at its peak, HR and 
blood pressure measures, as well as BL-VAS ratings, were obtained for a second time. This is 
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referred to as Time 2 (T2). Participants then completed the computerized tasks - the GNG, 
followed by the BART and the SST.  
 
Task order was the same for all participants to avoid any interactions of task order and differences 
in the onset of physiological responses to the drug between participants. After completing all tasks, 
HR and blood pressure measures were recorded for one final time. This is referred to as Time 3 
(T3). Participants also completed the BL-VAS one further time, were debriefed about the 
experiment, and received monetary compensation for their time. An outline of the entire 
experimental procedure is shown in Figure 3. 
2.6 Analyses 
 
2.6.1 Time effects of pramipexole 
To compare the physiological effects of pramipexole and placebo across time in the experiment, 
separate 2 x 3 mixed ANOVAs with Medication (placebo vs. pramipexole) as the between-subjects 
variable and Time (T1 vs. T2 vs. T3) as the within-subjects variable were conducted on HR, 
Figure 3: Schematic outline of the experiment. 
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diastolic and systolic blood pressure, and on the BL-VAS ratings. T1 measurements were taken 
right after capsule ingestion; T2 measurements were taken two hours after capsule ingestion; T3 
measurements were taken approximately 2 hours and 45 minutes after capsule ingestion (after 
behavioral tasks). 
2.6.2 Go/No-Go Task 
A series of independent samples t-tests were conducted on overall GNG accuracy and Go-trial RT. 
Overall GNG accuracy is commonly used as a measure of cognitive control and inhibition of pre-
potent responses. A lower accuracy on the GNG is generally due to higher error rates on NoGo 
trials, an indicator of increased impulsivity. Average Go-Trial RT was used as a more direct and 
continuous measure of impulsivity in ms as opposed to a binary correct vs. incorrect measure. A 
quicker average RT on Go trials would indicate that participants were more predisposed to making 
a response, whereas a slower RT would mean participants needed more time to generate or execute 
a response, thus were less impulsive.  
 
2.6.3 Stop Signal Task 
Stop-signal RT (SSRT), which is the main outcome measure of the task, was calculated by 
subtracting the SSD from the average RT (see Logan et al., 1984). An independent samples t-test 
was used to compare the average SSRT of the pramipexole and the placebo group. SSRT is a 
measure of the unobservable Stop process involved in inhibiting the Go process once a Stop-
signal is heard but a response is still ongoing. In order to calculate the SSRT, two conditions 
have to be met: 1) The accuracy on Stop trials must be around 50% and 2) mean RT for failed 
Stop trials must be shorter than the RT for Go trials (Claassen et al., 2015). 
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2.6.4 Balloon Analogue Risk Task 
An independent samples t-test was conducted to compare adjusted average number of pumps 
between groups. The adjusted average number of pumps is the average number of pumps, 
excluding trials on which the balloon popped. This is done because popped trials have a fixed limit 
on the number of pumps for each participant, such that even if some participants were to continue 
pumping more than others, they would be unable to do so because they were limited by the 
balloon’s breakpoint. There exist other variables that can be compared on the BART such as 
overall number of pumps, or the number of exploded balloons. To minimize the risk of Type 1 
error, analyses on these variables were not performed and the a priori hypothesis was made about 
the average adjusted number of pumps. This is a procedure similar to that originally used by Lejuez 
and colleagues, (2002). The adjusted average number of pumps is a measure of risky, reward-
dependent impulsivity involved in gambling, as the more pumps a person makes, the greater the 
reward but the more they risk that the balloon explodes and all earnings for that balloon are lost.   
 
A 2 x 3 mixed ANOVA with Medication as the between-subjects variable and Block (first set of 
10 balloons, second 10 balloons, and third 10 balloons) as the within-subjects variable was 
conducted on the adjusted average number of pumps. This analysis allows examining whether risk-
taking behavior changed in later blocks compared to earlier ones (practice trials were not included 
in this analysis).  
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Chapter 3: Results 
Data from one male and four females were excluded because they were unable to complete the 
entire testing protocol due to adverse side effects of the medication (nausea, fatigue, and 
dizziness). The following analyses were all carried out at an alpha level of 0.05, and Bonferroni 
corrections were used for post-hoc pairwise comparisons.  
3.0 Demographics and questionnaires 
Demographic data along with trait questionnaire scores and cognitive questionnaire scores are 
shown in Table 1. The pramipexole and placebo groups did not show significant differences on 
any of the variables (p > 0.05 for all variables; age t (38) = −0.84; education t (38) = −0.49; BDI 
t (38) = 0.78; BAI t (38) = 0.50; SAS t (38) = 0.23; Happiness t (38) = −0.06; Sleepiness t (38) = 
0.42; BIS t (38) = 1.00; Sensation Seeking Scale t (38) = −0.15; ANART t (38) = 0.14; MOCA   
t (38) = 0.00; COWAT FAS t (38) = 0.46; COWAT Animal t (38) = − 0.14). This rules out any 
pre-existing differences between the pramipexole and the placebo group on any of these 
measures which might have affected performance on the impulsivity tasks, including age, 
cognitive ability, trait impulsivity, and other potentially important variables. 
 
 Placebo Pramipexole 
Age 20.5 (1.3) 20.8 (0.9) 
Gender 8 M; 12 F 8 M; 12 F 
Handedness 18 R; 1 L; 1 Both 17 R; 2 L; 1 Both 
Education 15.40 (1.05) 15.5 (0.89) 
BDI 9.60 (7.18) 8.05 (5.26) 
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BAI 8.60 (8.29) 7.45 (6.17) 
SAS 11.50 (4.80) 11.20 (3.44) 
Happiness 4.45 (0.58) 4.46 (0.64) 
Sleepiness 10.05 (2.65) 9.60 (3.94) 
BIS 62.05 (10.29) 58.60 (11.41) 
Sensation Seeking 
Scale 
19.80 (5.72) 20.05 (4.47) 
ANART 118.95 (6.46) 118.71 (4.44) 
MOCA 27.80 (1.51) 27.80 (1.94) 
COWAT FAS 40.15 (11.00) 38.60 (10.61) 
COWAT Animals 24.55 (1.12) 24.80 (1.33) 
Table 1: Demographic measures and questionnaire scores of the pramipexole and placebo 
groups. 
 
3.1 Physiological measures 
Heart Rate - A 2 x 3 mixed measures ANOVA (Medication x Time) revealed a main effect of 
Time [F (2, 74) = 32.40, MSe = 25.12, p < .001, Ƞ2 = .47]. As can be seen in Figure 4, this effect 
is due to a decrease in HR from T1 to T2, and from T1 to T3 (both p < .001). There was also a 
significant Medication x Time interaction [F (2, 74) = 4.37, MSe = 25.12, p= .016, Ƞ2 = .11]. The 
difference in HR between T1 and T2, and T1 and T3 in the placebo group was 9.5 and 11.79, 
respectively. The difference in HR between T1 and T2, and T1 and T3 in the pramipexole group 
was 4.5 and 5.4, respectively. Thus, the differences between T1 and both T2 and T3 were larger 
in the placebo group than in the pramipexole group. The main effect of Medication was not 
significant [F (1, 36) = 0.084, p = .774], however, meaning that pramipexole had no effect on HR 
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independently of the passage of time or the time of ingestion. Mauchly’s test of sphericity has not 
been violated.  
  
 
Blood pressure- Separate 2 x 3 repeated measures ANOVAs were conducted on diastolic and 
systolic blood pressure. For diastolic blood pressure, Mauchly’s test indicated the assumption of 
sphericity was not met [X2 (2) = 9.6, p = .008]. This was due to the variance of differences in both 
groups in T3 - T2 being lower than in the other comparisons (i.e. T2 - T1 and T3 - T1). After 
Huynh-Feldt corrections (ɛ = 0.81), there was a significant main effect of Time [F (1.74, 74) = 
6.51, MSe = 28.68, p = .004, Ƞ2 = .123]. Post hoc Bonferroni corrected pairwise comparisons 
revealed that this was due to diastolic blood pressure decreasing from T1 to T2 (p = .017), and 
from T1 to T3 (p = .034), in both the pramipexole and the placebo group (see Figure 5). There was 
60
65
70
75
80
T1 T2 T3
H
ea
rt
 r
at
e 
(p
u
ls
e
, b
ea
ts
/m
in
u
te
)
Time
Heart rate over time
Pramipexole
Placebo
Figure 4: Mean HR over time in the placebo and pramipexole groups. Error bars represent 
SEM. 
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no main effect of Medication [F (1, 37) = 0.180, p = .674], and no Medication x Time interaction 
[F (1.74, 74) = 0.500, p = 0.583]. These results indicate that participants in the pramipexole and 
the placebo groups had higher diastolic blood pressure at the beginning of the testing session (T1) 
than 2 hours later (T2) or at the end of the session (T3). Pramipexole did not change participants’ 
blood pressure readings in comparison to placebo.   
 
 
 
 
For systolic blood pressure, Mauchly’s test also revealed a violation of the assumption of sphericity 
due to the variance of differences in both groups in T3 - T2 being lower than in the other 
comparisons. Due to the lower epsilon (ɛ = 0.67), and according to Girden (1992), a Greenhouse-
Geisser correction was applied and the effect of time was not significant [F (1.35, 74) = 3.54, p = 
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Figure 5: Diastolic blood pressure over time in the placebo and pramipexole groups. Error 
bars represent SEM. 
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.054]., The effect of Medication and the Medication x Time interaction were also not significant 
(see Figure 6, all p’s > .05). 
 
Figure 6: Systolic blood pressure over time in the placebo and pramipexole groups. Error bars 
represent SEM. 
 
Mood ratings - The BL-VAS ratings across the time points in both groups were compared using a 
2 x 3 repeated measures ANOVA. There was a significant effect of Time [F (2, 76) = 13.65, MSe 
= 1748.37, p < .001, Ƞ2 = .264]. Bonferroni-corrected pairwise comparisons revealed this was due 
to an overall decrease in alertness ratings from T1 to T2 (p = .001) and T2 to T3 (p < .001; see 
Figure 7). This main effect was qualified by a Medication x Time interaction [F (2, 76) = 4.11, 
MSe = 526.62, p = .020, Ƞ2 = 0.098]. This was due to the alertness scores significantly decreasing 
from T1 to T2 and T1 to T3 in the pramipexole group (p’s < .001), but not in the placebo group (p 
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= .84, and .31, respectively). The main effect of Medication was not significant [F (1, 38) = 2.63, 
p = .113]. Mauchly’s test of sphericity has not been violated.  
 
Figure 7: Alertness ratings from the Bond-Lader Visual Analogue Scale over time in the placebo 
and pramipexole groups. Error bars represent SEM. 
 
3.2 Behavioral measures 
 
3.2.1 Go/No-Go Task 
Performance on the GNG for both groups, including accuracy and RT, is shown in Table 2. To 
compare accuracy on the GNG between the placebo and pramipexole group, an independent 
samples t-test was used. Levene’s test showed that variances were unequal between the groups; a 
corrected value was used for the t-test, and revealed a significant difference between the groups,  
t (28.3) = 2.72, p = .011, d = 0.86, with the pramipexole group having a lower accuracy. To further 
explore whether this difference occurred due to errors on Go or on NoGo trials, separate t-tests 
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were conducted on both accuracy measures. There was a significant difference in accuracy 
between the placebo and pramipexole groups on Go trials [t (28.7) = 2.24, p = .033, d = 0.71, 
corrected for unequal variances], with the pramipexole group having a lower accuracy than the 
placebo group. The only error that is possible on a Go trial is timing out without making a response, 
and as seen in Error! Reference source not found., the pramipexole group had twice as many t
imed-out Go trials as the placebo group, t (29.1) = 2.26, p = .031, d = 3.22. This is suggesting an 
inhibition or stunting of a pre-potent and impulsive motor response in the pramipexole group. The 
accuracy for NoGo trials was not significantly different between the placebo and pramipexole 
groups, t (38) = 1.30, p = .20. To examine whether there might have been a general cognitive or 
response slowing on the GNG, Go and NoGo trial RTs were compared between the placebo and 
pramipexole groups using two tailed independent samples t-tests. There were no significant RT 
differences between the groups in either Go [ t (38) = −0.574, p = 0.569] or NoGo [ t (38) = 1.315, 
p = 0.196] trials. This rules out the explanation that the larger number of timeout Go trials in the 
group that received pramipexole was due to a general cognitive slowing effect, as the RTs were 
not significantly longer in the pramipexole group in either Go or NoGo trials. Thus, the inability 
to respond in time on a Go trial was unique to the pramipexole group only, supporting our 
hypothesis of decreased motor impulsivity in participants who received pramipexole. 
 
 Placebo Pramipexole 
Overall accuracy 0.94 (0.004) 0.91 (0.009) 
Go accuracy                      * 0.96 (0.006) 0.93 (0.01) 
Go RT 356.76 (26.23) 361.70 (28.17) 
NoGo RT 487.19 (56.19) 470.28 (12.32) 
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Number of Go timeouts     * 6.8 (1.2) 12.5 (2.2) 
Number of NoGo errors 8.3 (1.0) 9.3 (1.1) 
SSRT 295.54 (32.16) 301.80 (34.32) 
BART adjusted pump # 22.2 (2.7) 19.3 (1.1) 
Table 2: Performance on the GNG, SST, and BART in the placebo and pramipexole groups. 
Values are given as mean (SEM), * denotes p < .05. 
 
3.2.2 Stop Signal Task 
Participants in the placebo group had a successful inhibition rate of 40% (SD = 8%), and 
participants in the pramipexole group had a rate of 39% (SD= 14%). An independent samples t-
test revealed no significant difference between these rates, t (38) = 0.43, p = .67. The mean RT of 
failed Stop trials was shorter than the mean RT of Go trials, [Failed Stop trial RT= 412 (118) ms, 
Go trial RT = 456 (149) ms]. As a main measure of motor impulsivity, the SSRT for each 
participant was calculated by taking the mean Go RT and subtracting the mean SSD. An 
independent samples t-test was used to compare the SSRT of the two groups. The average SSRT, 
which measures the Stop process RT, was compared between the placebo (M = 295.54, SEM = 
32.16) and pramipexole (M = 301.80, SEM = 34.32) groups, and revealed no significant difference, 
t (38) = 0.596, p = .555. Thus, the pramipexole and placebo groups did not take a significantly 
different amount of time to complete the Stop process.  
 
3.2.3 Balloon Analogue Risk Task 
The adjusted average number of pumps, which is a measure of the participants’ riskiness and 
tendency to continue pumping a balloon in anticipation of a larger reward, was compared between 
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the placebo (M = 22.2, SEM = 2.7) and pramipexole (M = 19.3, SEM = 1.1) groups. There was no 
significant difference between the groups on the adjusted average number of pumps, t (38) = 0.999, 
p = .324, suggesting that pramipexole did not alter participants’ risk-taking in gambling-like 
situations. The Medication x Block ANOVA on adjusted pumps revealed a main effect of Block, 
F (2, 74) = 3.99, p = .022, MSe = 53.81 , Ƞ2 = . 098 (see Figure 8). Bonferroni corrected post-hoc 
analyses revealed that the adjusted average number of pumps in Block 2 was significantly lower 
than in Block 3. Block 1 did not significantly differ from Block 2 or Block 3. These findings 
indicate that participants in both groups engaged in more risky-responding on the final block of 
the task compared to the middle block. This could be a result of fatigue or increased confidence in  
performance of the task. There was no significant main effect on Medication, or a                 
Medication x Block interaction. Mauchly’s test of sphericity has not been violated.  
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41 
 
 
Chapter 4: Discussion 
4.0 Summary of results 
In the current study, young healthy participants were given a dose of the dopamine agonist 
pramipexole, or a placebo, and then completed tasks measuring motor impulsivity and risk-taking. 
We used three tasks to measure different aspects of impulsivity: the GNG task and the SST to 
measure motor impulsivity, and the BART to measure risk-taking and gambling. Results indicated 
that participants who received pramipexole had more timed out Go trials than the participants who 
received placebo, but there were no RT differences in either Go or NoGo trials. This suggests 
enhanced motor inhibition, thus evidence of decreased motor impulsivity in the pramipexole 
group, which agrees with our proposed hypothesis and the literature. There was no significant 
SSRT difference between the groups on the SST. Performance on the BART was also not different 
between the placebo and the pramipexole groups, indicated by no difference in the adjusted 
average number of pumps. These results align with the hypothesis that different aspects of 
impulsivity might not be affected equally by dopamine agonists such as pramipexole.  
4.1 Demographic, cognitive, and affective measures 
Lack of differences between the groups on any of the demographic, cognitive, or affective 
measures confirms that the randomization process produced groups similar in these important 
characteristics. Particularly, there were no differences in pre-existing impulsivity, a factor which 
has been shown to exacerbate the influence of dopaminergic medication on impulsivity 
(Claassen et al., 2015; MacDonald et al., 2016). Therefore, because both groups were equivalent 
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on these measures before drug administration and before the drug had time to take effect, results 
on the behavioral tasks are not due to any pre-existing differences between the groups.  
4.2 Physiological changes 
As the experiment progressed, participants showed a decrease in HR and in alertness scores on 
the BL-VAS. Because there was no main effect of medication on these measures, we interpret 
these decreases as being a result of participants becoming more comfortable with the 
experimental setting, and being seated and inactive for nearly 3 hours. The Medication x Time 
interaction indicates that participants who received pramipexole had greater differences in BL-
VAS ratings from T1 to T2 and T3 than those who received placebo. Nevertheless, even at T3, 
when scores were lowest, the pramipexole participants’ average scores on the BL-VAS centered 
around ‘Neutral’, indicating they were not feeling particularly tired or sleepy. Additionally, the 
equivalent RTs between the placebo and pramipexole groups mean that this decrease in alertness  
did not affect RTs and that our finding of more timed out Go trials in the pramipexole group is 
not simply due to a decrease in alertness.  
4.3 Motor impulsivity  
Our findings suggest that pramipexole does not increase motor impulsivity, and might in fact 
decrease it, in line with other experiments that find either unchanged or decreased motor 
impulsivity after administration of dopamine agonists (Caillava-Santos et al., 2015; Fera et al., 
2007; Hiebert et al., 2014; Müller, Benz, & Börnke, 2001; Müller, Benz, & Przuntek, 2002; 
Nandam et al., 2013; van Wouwe et al., 2016). It is important to note that participants on 
pramipexole had more timed out Go trials than those who received placebo, but did not have 
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longer RTs on the GNG task, or on the other tasks. Thus, it is unlikely that the higher number of 
timed out trials is simply due to an overall slowing effect or a motor impairment due to 
pramipexole.  Rather, they seemed to have imposed a slightly more conservative criterion for 
responding in the Go trials (i.e., less motor impulsivity). This pattern suggests that participants 
on pramipexole were in fact exhibiting a decrease in impulsive behavior.  
 
There was no corresponding difference between the placebo and pramipexole groups in the 
number of commission errors on NoGo trials, as would have been predicted if pramipexole 
improves motor impulsivity. It is possible that we did not find fewer commission errors for the 
pramipexole relative to the placebo group because of our 3:1 ratio of Go:NoGo trials, meaning 
there were far fewer NoGo trials and therefore less power to detect subtle differences across 
groups owing to medication in the NoGo condition. Indeed, there were very few NoGo errors 
overall in either group. We used the chosen ratio to ensure the development of a pre-potent Go 
response (Boucher et al., 2012; Kiehl et al., 2000; Petit et al., 2012; Rubia et al., 2001) that 
would engender an impulsive motor action in the NoGo condition. In future studies, more blocks 
and hence trials overall would be advisable. Alternatively, a different ratio of Go:NoGo trials 
might be considered though the latter approach could result in a failure to induce the pre-potent 
motor response.   
 
The experiment by Hamidovic and colleagues (2008) showed that pramipexole did not have an 
effect on GNG performance in healthy controls, whereas we found more timed out Go trials. 
This discrepancy may be due to differences between the GNG tasks used. Hamidovic and 
colleagues employed a more complex GNG task, with four stimuli corresponding to Go 
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responses and four corresponding to NoGo responses. This complexity and the need to remember 
stimulus-response associations in addition to executing motor responses or inhibiting them 
confounds motor impulsivity and working memory, potentially accounting for the differences in 
their findings. They also used a 1:1 ratio of Go:NoGo trials.  In using one Go and one NoGo 
stimulus in our task, and employing a 3:1 ratio of Go:NoGo trials, we ensured that the task 
measured motor impulsivity more clearly and promoted the development of a pre-potent motor 
response. Additionally, due to the small sample size in their study (N=10), they were potentially 
underpowered to detect subtle medication effects on impulsivity. 
 
Although we could not find any other studies that have investigated the effect of pramipexole on 
GNG performance in healthy controls, a few similar studies have been conducted with PD 
patients on and off medication (Antonelli et al., 2014; Farid et al., 2009; Herz et al., 2014). In a 
small positron emission tomography study (N = 7) of PD patients performing a GNG and a 
delayed discounting task on and off pramipexole, Antonelli and colleagues (2014) found no 
influence of pramipexole on RT or errors on the GNG. A functional magnetic resonance imaging 
(fMRI) study by Farid and colleagues (2009), tested PD patients (N = 9) on and off levodopa in 
contrast with healthy controls and found that there was no medication effect on GNG 
performance. Herz and colleagues (2014) also found no medication effects on performance of a 
more complex GNG task in an fMRI study of 13 PD patients with dyskinesia and 13 without 
dyskinesia, tested on and off their regular dopaminergic medication. The GNG task consisted of 
three stimuli, thus it was more complex and less likely to elicit pre-potent responses. The few 
experiments that investigated the effects of dopaminergic medication on GNG performance in 
PD patients found no behavioral differences between patients on and off medication. However, 
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all the studies tested only a small sample of participants, and were very likely underpowered to 
detect medication effects. Further, the use of complex tasks and less emphasis on inducing a pre-
potent motor response could have undermined these studies.     
 
Another task commonly used to measure motor inhibition is the SST (Bedard et al., 2002; Eagle, 
Baunez, et al., 2008; Williams et al., 1999). We did not find SSRT differences on the SST 
between the placebo and pramipexole groups. Indeed, results from the SST and the GNG task do 
not always correspond and a PCA has shown the two tasks load on different factors (Caswell et 
al., 2015). The tasks, although similar, reflect different inhibitory processes. Schachar and 
colleagues, (2007) proposed a distinction between ‘motor restraint’ and ‘motor cancellation’. 
The SSRT measures the time taken to complete a ‘stopping’ process once an action has already 
been selected and initiated (Dalley et al., 2011; Winstanley, 2011). In this way, it is measuring 
‘motor cancellation’. This is different from the motor inhibition process in the GNG, which 
measures the ability to inhibit the initiation of a response (Dalley et al., 2011; Eagle, Baunez, et 
al., 2008; Reynolds, Penfold, & Patak, 2008; Winstanley, 2011; Winstanley et al., 2010). This 
process is therefore one of ‘motor restraint’. The two processes elicited by these tasks have also 
been shown to have distinct neural activation patterns and dissociable pharmacology (Eagle, 
Bari, & Robbins, 2008; Rubia et al., 2001).  
 
We are aware of only three studies that investigated the effects of dopaminergic medication on 
SST performance in healthy controls. Farr and colleagues, (2014) gave 25 healthy controls a 
single dose of the dopamine reuptake inhibitor methylphenidate (45 mg) and asked them to 
complete the SST while placed in an fMRI scanner. Data from these participants was compared 
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to a demographically-matched sample of participants who did not receive any drugs but 
completed the task in a different experiment. Results indicated that methylphenidate did not 
affect any behavioral measures of performance on the SST. A within-subjects, placebo-
controlled study by Costa and colleagues, (2013) tested 54 healthy controls on placebo and on 
methylphenidate. They found no differences in SST performance between participants whether 
they received methylphenidate or a placebo. Another within-subjects placebo controlled 
experiment by Nandam and colleagues (2013) examined the effects of a single dose of the 
dopamine agonist cabergoline (1.25 mg) on SST performance in healthy controls. Participants 
showed a faster SSRT on cabergoline compared to placebo, suggesting that cabergoline 
improved impulse control by speeding up the stopping process of the SST. However, the version 
of the task employed in this experiment contained a high number of trials (512) in comparison to 
the task employed in other experiments (e.g. 234 trials in Costa et al., 2013). Thus it is possible 
that the effects of dopaminergic medication on SST are very small and can only be detected with 
a very large number of trials. Additionally, cabergoline is a D2 agonist, whereas methylphenidate 
acts through a different mechanism, by blocking the reuptake of dopamine from the synapse.  
Based on the findings of these studies, it appears that SST performance is not very sensitive to 
dopaminergic drugs, which would be in line with the pattern of findings in our study.  
 
Studies of PD patients on and off dopaminergic medication also suggest that there is little 
influence on SST performance. Obeso, Wilkinson, and Jahanshahi, (2011) tested 17 patients with 
PD in two sessions, one on and one off levodopa. They found no differences on any measure of 
SST between on and off sessions. Claassen and colleagues (2015), tested 24 patients with PD on 
and off dopamine agonists (although half the sample was also on concomitant levodopa 
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treatment). The PD group was split based on the presence of ICDs (12 PD with ICD, 12 without 
ICD). The authors found no difference in performance on the SST between sessions on and off 
dopaminergic medication. From the limited number of studies that have looked at the effects of 
dopaminergic drugs on performance of the SST, it seems likely that if there is any effect on 
SSRT and thus impulse control, it is a very small effect that requires a large number of trials to 
uncover. Thus, one potential explanation for the null results of the SST in our study is that our 
version of the task did not contain enough trials to detect such a small change.  
4.4 Cognitive impulsivity  
Cognitive impulsivity, although related to motor impulsivity, is certainly distinct from it. We 
used the BART to measure cognitive impulsivity, specifically risk-taking and gambling-like 
behaviour. In our experiment, we found no differences between participants who received 
pramipexole and those who received placebo on the BART. Claassen and colleagues, (2011) 
aimed to examine the effects of dopaminergic medication on risk-taking in PD patients with 
ICDs (N= 22) and without ICDs (N=19). They found that in the PD without ICD group, there 
was no difference in risk-taking on the BART between the on and off medication testing 
sessions. However, in the PD with ICD group, there was evidence of increased risk-taking in the 
session on medication compared to off medication. Thus, dopaminergic medication alone did not 
increase risk taking. In another study, Simioni, Dagher and  Fellows, (2012) tested 23 PD 
patients on and off dopaminergic medication. They found that although medication had no 
overall effect on risk-taking on the BART, it did increase risk-taking across the 3 blocks of the 
BART. That is, PD patients increased the number of pumps from the 1st to the 3rd block of the 
BART when tested on medication more than they did when tested off medication. These results 
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suggest that medication effects on risk-taking are more subtle and might require some time 
before they influence behavior. Finally, a study by MacDonald and colleagues (2016) 
specifically tested the hypothesis that medication effects on risk-taking are dependent on initial 
dopamine levels and predisposition for risky behavior using gene polymorphisms in older 
healthy controls (N=28). Over three testing sessions, participants received ropinirole (0.5 or 1.0 
mg) or placebo. Using mixed-model linear regression, they found that controls with a high basal 
dopamine neurotransmission (measured through gene polymorphisms) exhibited more risk-
taking behavior on ropinirole versus placebo, only following negative but not positive 
reinforcement (i.e. trials on which the balloon popped versus trials they cashed out). The pattern 
of findings above indicates that dopamine agonists’ effects on risk-taking are dependent on 
initial predisposition to risky behavior and impulsivity (measured either through clinical 
assessments or gene polymorphisms). Thus, dopaminergic medication alone is not sufficient to 
lead to more impulsivity and risk-taking.  
4.5 Limitations  
In this study, conducted with healthy volunteers, participants received a single dose of a 
dopamine agonist. The dose (0.5 mg) was not as large as the dose prescribed to clinical 
populations, because dopamine agonist dosage needs to be increased gradually over a longer 
period of time to avoid side effects. Studies that have found an association between dopamine 
agonist use and ICDs (Cools, Barker, Sahakian, & Robbins, 2003; Pontone et al., 2006; 
Weintraub et al., 2010) have all been conducted in clinical populations, with patients who have 
been treated with dopaminergic medication for a long duration. The current study was not 
longitudinal so it was impossible to examine any long-term effects of pramipexole. Additionally, 
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we could not safely administer a higher dose of the drug, and this was the dosage commonly 
used in other studies that administered pramipexole to healthy participants (Hamidovic et al., 
2008; Pizzagalli et al., 2008; Riba et al., 2008). Administering a larger dose would most likely 
increase the occurrence of adverse effects that lead to participant drop-out. Thus, it is possible 
that a single (and comparatively low) dose of pramipexole administered to healthy controls does 
not have enough potency to effect the changes that lead to ICDs and increased risk-reward 
impulsivity. Pramipexole’s effects on impulsive behaviors may need time to build up, and such 
effects were not investigated in this study. 
 
It is important to note that out of the four participants whose data was discarded, three were 
females, who had a lower body mass index than the one male. Other studies of healthy controls 
that administered pramipexole either excluded females (Riba et al., 2008; Samuels, Hou, 
Langley, Szabadi, & Bradshaw, 2006; Samuels, Hou, Langley, Szabadi, & Bradshaw, 2007; Ye 
et al., 2011) or excluded participants below a certain body mass index (Hamidovic et al., 2008; 
Pizzagalli et al., 2008; Santesso et al., 2009). We chose to include all participants in our study to 
increase generalizability, however, future studies need to weight generalizability versus the 
chance of participant drop-out.  
 
Additionally, in our study we were not able to analyze results based on our participants’ 
predisposition to, or presence of, impulsive behavior, because all participants scored similarly on 
the baseline impulsivity measures. Other studies may wish to look at gene polymorphisms in 
young healthy controls as a moderating variable of the effect of dopaminergic medication on 
impulsivity. 
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Finally, it is important to note that participant performance on the SST in this experiment was 
such that appropriate analysis of the SST was not possible. One of the conditions that needs to be 
met for a proper interpretation of the SST is that participant accuracy is approximately 50%. In 
our experiment, the average accuracy was around 40%, suggesting that participants either did not 
understand the instructions, or that there were not enough trials for participants to develop 
competency with the task. Thus, it is possible that the results of the SST would be different in 
our study given more SST trials. 
4.6 Conclusion 
Dopamine agonists are commonly prescribed to treat the motor symptoms of PD, RLS, as well as 
some cases of mood disorders, and addiction treatments. Studies have found an association 
between dopaminergic medication and ICDs in patients with PD, suggesting that dopamine 
agonists may increase impulsive behavior. At the same time, experiments directly investigating 
the effects of dopaminergic medication on impulsivity measures found a decrease in impulsivity 
after dopaminergic medication. The current study hypothesized that dopamine agonists decrease 
some aspects of impulsivity, particularly motor impulsivity, and may increase other aspects of 
impulsivity, such as risk-taking and gambling. To test this hypothesis, healthy young adults were 
given pramipexole, or a placebo pill, and asked to perform tasks measuring impulsivity. The 
three chosen tasks were the GNG and the SST to measure motor impulsivity, and the BART to 
measure risk-taking and gambling. 
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Participants who received pramipexole had more timed-out Go trials on the GNG than those who 
received placebo. This is supporting the proposed hypothesis that pramipexole decreases motor 
impulsivity and in fact leads to a delayed response compared to controls who received placebo. 
There was no difference between the two groups in the SST, which is possibly due to differential 
effects of pramipexole on motor cancellation (as in the SST) as opposed to motor restraint (as in 
the GNG), and also due to conditions not being met for appropriate analysis. On the BART, there 
was also no difference between the pramipexole and the placebo groups. Similar studies have 
found that dopaminergic medication effects on the BART are moderated by a predisposition to 
impulsivity as measured by gene polymorphisms. Therefore, it is likely pramipexole decreases 
some aspects of motor impulsivity such as action restraint, and may also increase other aspects of 
impulsivity such as risk taking, if there is a predisposition for such behavior. 
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Appendix V: American National Adult Reading Test wordlist 
1. ache 
 
23. papyrus 
 
45. caprice 
2. debt 
 
24. asthma 
 
46. demesne 
3. pint 
 
25. hiatus 
 
47. imbroglio 
4. depot 
 
26. simile 
 
48. hyperbole 
5. chord 
 
27. blatant 
 
49. syncope 
6. bouquet 
 
28. cellist 
 
50. prelate 
7. deny 
 
29. zealot 
  
8. capon 
 
30. abstemious 
  
9. heir 
 
31. meringue 
  
10. aisle 
 
32. placebo 
  
11. subtle 
 
33. façade 
  
12. nausea 
 
34. pugilist 
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13. gauge 
 
35. virulent 
  
14. naïve 
 
36. worsted 
  
15. thyme 
 
37. détente 
  
16. courteous 
 
38. anise 
  
17. algae 
 
39. sieve 
  
18. fetal 
 
40. chassis 
  
19. quadruped 
 
41. beatify 
  
20. epitome 
 
42. scion 
  
21. superfluous 
 
43. cabal 
  
22. chamois 
 
44. apropos 
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